ASP Isotopes

ASP Isotopes EBIT Growth

The Year-over-Year EBIT Growth of ASP Isotopes (ASPI) as of Nov 18, 2026 is -117.01 %. In the previous year, Year-over-Year EBIT Growth was -64.28 % — a change of 82.03% (lower).

EBIT Growth

-117.01 %

YoY

82.03%

Last updated:

Year-over-Year EBIT Growth of ASP Isotopes is 2025 -117.01 % . Year-over-Year EBIT Growth of ASP Isotopes was 2024 -64.28 % . It decreases by 82.03% lower compared to the previous year.

The ASP Isotopes EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2021
74.57 USD
Jan 1, 2022
-95.51 USD
Jan 1, 2023
-214.61 USD
Jan 1, 2024
-64.28 USD
Jan 1, 2025
-117.01 USD
The ASP Isotopes EBIT Growth history
YEAREBIT GrowthYoY
-117.01 %+82.03%
-64.28 %-70.05%
-214.61 %+124.69%
-95.51 %-228.08%
74.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ASP Isotopes Stock analysis

What does ASP Isotopes do? ASP Isotopes, Inc. generates revenue through the development and commercialization of enriched isotopes using its Aerodynamic Separation Process (ASP technology). The company focuses on producing Carbon-14 (C-14), Molybdenum-100 (Mo-100), and Silicon-28 (Si-28) for specialized markets, with plans to expand into Uranium-235 (U-235) for the nuclear energy sector. Its subsidiaries, ASP Isotopes Guernsey Limited and Enriched Energy LLC, handle high-value isotope production and uranium development, respectively. The company licenses ASP technology from Klydon Proprietary Ltd for all isotope-related activities. The target customers for C-14, Mo-100, and Si-28 are highly specialized end markets requiring low-volume, high-value isotopes. Enriched Energy LLC specifically targets the nuclear energy market with uranium products. ASP Isotopes Guernsey Limited focuses on niche applications where isotope enrichment is critical, such as medical and industrial uses. The company’s revenue model relies on the sale of these enriched isotope products to specialized industries rather than mass-market consumers. ASP Isotopes, Inc. operates under a pre-commercial stage, meaning it is still developing its production capabilities and has not yet achieved full-scale commercialization. The company’s initial revenue streams will come from the sale of C-14, Mo-100, and Si-28, with future expansion into U-235 expected to diversify its product portfolio. The Aerodynamic Separation Process (ASP technology) is central to its business model, enabling the enrichment of natural isotopes into higher concentration products for specialized applications. ASP Isotopes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ASP Isotopes stock

Year-over-Year EBIT Growth of ASP Isotopes is -117.01 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth ASP Isotopes since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's ASP Isotopes historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ASP Isotopes

All Key Metrics — ASP Isotopes